Stock RTWG RTW BIOTECH OPPORTUNITIES LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials RTW Biotech Opportunities Ltd

Equities

RTWG

GG00BKTRRM22

Closed End Funds

Delayed London S.E.
Other stock markets
 09:01:23 2024-05-09 am EDT 		5-day change 1st Jan Change
1.34 USD -0.74% Intraday chart for RTW Biotech Opportunities Ltd +1.52% -4.46%
Apr. 05 RTW Biotech invests in cell and gene therapy company Obsidian AN
Apr. 02 EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises AN

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 221.3 360 378.1 257
Enterprise Value (EV) 1 210.6 355.5 371.6 250
P/E ratio 5.72 x 2.24 x -5.88 x -6.52 x
Yield - - - -
Capitalization / Revenue 2,734,257,024 x 2,336,391,298 x 574,810,195 x 118,578,747 x
EV / Revenue 2,601,676,237 x 2,306,843,386 x 564,951,510 x 115,364,471 x
EV / EBITDA - - - -
EV / FCF -6,011,979 x 28,375,598 x 15,395,838 x -5,886,977 x
FCF Yield -0% 0% 0% -0%
Price to Book 1.03 x 0.87 x 0.98 x 0.79 x
Nbr of stocks (in thousands) 161,545 191,516 212,389 212,389
Reference price 2 1.370 1.880 1.780 1.210
Announcement Date 4/22/20 4/29/21 3/30/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022
Net sales - 0.0809 0.1541 0.6577 2.167
EBITDA - - - - -
EBIT 1 -0.0706 -1.28 -4.879 -7.581 -4.511
Operating Margin - -1,581.85% -3,166.32% -1,152.71% -208.16%
Earnings before Tax (EBT) 1 27.92 38.72 160.7 -64.34 -39.44
Net income 1 27.92 38.72 160.7 -64.34 -39.44
Net margin - 47,834.08% 104,249.43% -9,783.3% -1,819.66%
EPS 2 0.1898 0.2397 0.8389 -0.3030 -0.1857
Free Cash Flow - -35.03 12.53 24.13 -42.47
FCF margin - -43,274.88% 8,129.67% 3,669.51% -1,959.66%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - 7.8% - -
Dividend per Share - - - - -
Announcement Date 4/22/20 4/22/20 4/29/21 3/30/22 3/31/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022
Net Debt 1 - - - - -
Net Cash position 1 0.03 10.7 4.55 6.48 6.97
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -35 12.5 24.1 -42.5
ROE (net income / shareholders' equity) - 27.6% 51.2% -16.1% -10.7%
ROA (Net income/ Total Assets) - -0.57% -0.96% -1.1% -0.67%
Assets 1 - -6,812 -16,771 5,841 5,881
Book Value Per Share 2 0.4500 1.330 2.150 1.820 1.540
Cash Flow per Share 2 0 0.0700 0.0200 0.0300 0.0300
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 4/22/20 4/22/20 4/29/21 3/30/22 3/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Closed End Funds

1st Jan change Capi.
RTW BIOTECH OPPORTUNITIES LTD Stock RTW Biotech Opportunities Ltd
-4.46% 520M
ARES CAPITAL CORPORATION Stock Ares Capital Corporation
+3.74% 12.63B
PERSHING SQUARE HOLDINGS, LTD. Stock Pershing Square Holdings, Ltd.
+12.07% 9.59B
SPROTT PHYSICAL URANIUM TRUST FUND Stock Sprott Physical Uranium Trust Fund
+10.01% 5.63B
FS KKR CAPITAL CORP. Stock FS KKR Capital Corp.
-2.85% 5.43B
PIMCO DYNAMIC INCOME FUND Stock PIMCO Dynamic Income Fund
+8.47% 5.33B
SPROTT PHYSICAL SILVER TRUST Stock Sprott Physical Silver Trust
+14.23% 4.48B
SPROTT PHYSICAL GOLD AND SILVER TRUST Stock Sprott Physical Gold and Silver Trust
+16.04% 4.41B
MACQUARIE KOREA INFRASTRUCTURE FUND Stock Macquarie Korea Infrastructure Fund
+2.17% 4.06B
3I INFRASTRUCTURE PLC Stock 3i Infrastructure plc
+7.53% 4.01B
Closed End Funds
  1. Stock Market
  2. Equities
  3. RTWG Stock
  4. Financials RTW Biotech Opportunities Ltd
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW